in vivo News and Research

RSS

Stem cell therapy for COVID-19 and ARDS

In a review paper recently uploaded to the journal Biomedicine & Pharmacotherapy by Mahendiratta et al. (May 2021) the applicability of stem cells in treating severe SARS-CoV-2 infection is investigated, with regard to ARDS therapy.

5 May 2021

Study could pave way for new therapies for kidney disease

Our kidneys are charged with the extraordinary task of filtering about 53 gallons of fluid a day, a process that depends on podocytes, tiny, highly specialized cells in the cluster of blood vessels in the kidney where waste is filtered that are highly vulnerable to damage.

5 May 2021

4D printing strategy helps fabricate biomimetic microchannel scaffold for spinal fusion

Spinal fusion is frequently performed to restore spinal stability in patients with spinal diseases, such as spinal stenosis, vertebral fractures, progressive deformities, and instability.

5 May 2021

Study shows potential of human mesenchymal stem cells to treat chronic lung infections

A study released today in STEM CELLS Translational Medicine offers hope for those suffering from a chronic, difficult to treat condition called non-tuberculous mycobacteria (NTM) lung infection.

4 May 2021

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

A vexing problem in the development of vaccines has been the need to achieve the right glycosylation profile for the viral antigens. A new study, recently released as a preprint on the bioRxiv* server, shows how a sequential cell-free approach produced complex N-glycans from simpler types, in a one-pot reaction.

4 May 2021

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

A new study, released as a preprint on the bioRxiv* server, reports promising results with the natural product hopeaphenol, which successfully prevented the entry of the virus into host cells.

3 May 2021

A new SARS-CoV-2 variant (HMN.19B) has been identified in France

New research published in the Centers for Disease Control and Prevention’s journal Emerging Infectious Diseases has confirmed the emergence of a new SARS-CoV-2 variant called HMN.19B from the viral clade 19B in France. The 19B viral clade — which includes the D614G variant — was prevalent in late 2019 but had since been rarely observed since early 2020 because of newer viral clades.

3 May 2021

Study reveals new broadly neutralizing and protective antibody against coronaviruses

In the setting of potentially reduced vaccine efficacy against coronavirus disease (COVID-19) due to emerging viral variants, the deployment of effective treatments based on monoclonal antibodies may be an additional strategy to help control the pandemic. A new study by US researchers, currently available on the bioRxiv* preprint server, describes the action of a specific antibody known as DH1047.

3 May 2021

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2).

3 May 2021

Could CRISPR be used as a SARS-CoV-2 antiviral?

The potential of using this gene manipulation technology as a SARS-CoV-2 inhibitor or prophylactic is investigated in a review recently uploaded to the journal Experimental Biology and Medicine (April 25th, 2021) by Arnab Banerjee and colleagues.

2 May 2021

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

Researchers in the United States and Austria have demonstrated the potential of a modified influenza virus as a vaccine to protect against viral respiratory pathogens, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

2 May 2021

Correcting mutations in muscle stem cells using new gene-editing technology

A new gene-editing technique can be used to correct mutations in muscle stem cells, paving the way for the first potential cell therapy for genetic muscle disorders.

30 Apr 2021

Hepatitis C antivirals synergize with remdesivir to inhibit SARS-CoV-2 in vitro

A new study sheds light on the potential of drug combinations to stem viral transmission and treat patients with COVID-19. It also shows that four drugs used to treat hepatitis C synergize with remdesivir to make it up to ten times more effective at inhibiting SARS-CoV-2 in cell cultures.

30 Apr 2021

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

Researchers in the Republic of Korea (South Korea), The Netherlands, and South Africa have demonstrated the potential of the monoclonal antibody CT-P59 as an effective therapeutic for coronavirus disease 2019 (COVID-19) caused by the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

29 Apr 2021

High-powered MRI detects subtle differences in the hippocampus of people with Down syndrome

Using ultra-high field magnetic resonance imaging (MRI) to map the brains of people with Down syndrome (DS), researchers from Case Western Reserve University, Cleveland Clinic, University Hospitals and other institutions detected subtle differences in the structure and function of the hippocampus--a region of the brain tied to memory and learning.

29 Apr 2021

Potent monoclonal antibody shows promise against emerging SARS-CoV-2 variants of concern

In a new study currently available on the bioRxiv* preprint server, a group of US-based researchers developed a panel of neutralizing monoclonal antibodies against SARS-CoV-2 that can block viral attachment to cells – and pinpointed a specific one that can potently neutralize all tested variants of concern.

28 Apr 2021

Peptide nucleocapsid vaccine candidate elicits protective T cell immunity against SARS-CoV-2 in vivo

A new study describes a synthetic peptide used as a platform to generate protective adaptive cellular immunity to the virus in rhesus macaques, which are the gold standard for preclinical testing in humans.

28 Apr 2021

Scientists identify blood cells most likely to be targeted by HIV during a real-life infection

In the 40-some years since the beginning of the HIV/AIDS epidemic, scientists have learned a lot about the virus, the disease, and ways to treat it. But one thing they still don't completely understand is which exact cells are most susceptible to HIV infection.

28 Apr 2021

Nanobodies neutralize SARS-CoV-2 in pre-clinical model

A team of Australian researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI), the Doherty Institute, and the Kirby Institute have identified neutralizing nanobody cocktails that block the SARS-CoV-2 virus from entering cells in pre-clinical models.

27 Apr 2021

Study reveals a hidden role of circulating microRNA as a driver of SARS-CoV-2 infection

In a methodological tour-de-force study, a large group of researchers from the USA and the United Kingdom analyzed patient transcriptomic data in-depth and discovered a circulating microRNA (miR-2392) that is directly implicated in the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) machinery during the infection process.

26 Apr 2021

in vivo News and Research

Stem cell therapy for COVID-19 and ARDS

Study could pave way for new therapies for kidney disease

4D printing strategy helps fabricate biomimetic microchannel scaffold for spinal fusion

Study shows potential of human mesenchymal stem cells to treat chronic lung infections

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

A new SARS-CoV-2 variant (HMN.19B) has been identified in France

Study reveals new broadly neutralizing and protective antibody against coronaviruses

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

Could CRISPR be used as a SARS-CoV-2 antiviral?

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

Correcting mutations in muscle stem cells using new gene-editing technology

Hepatitis C antivirals synergize with remdesivir to inhibit SARS-CoV-2 in vitro

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

High-powered MRI detects subtle differences in the hippocampus of people with Down syndrome

Potent monoclonal antibody shows promise against emerging SARS-CoV-2 variants of concern

Peptide nucleocapsid vaccine candidate elicits protective T cell immunity against SARS-CoV-2 in vivo

Scientists identify blood cells most likely to be targeted by HIV during a real-life infection

Nanobodies neutralize SARS-CoV-2 in pre-clinical model

Study reveals a hidden role of circulating microRNA as a driver of SARS-CoV-2 infection

eBook: Using iPSCs models for human disease research and drug discovery eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News